Survival according to BRAF-V600 tumor mutations - An analysis of 437 patients with primary melanoma

Diana Meckbach, Jürgen Bauer, Annette Pflugfelder, Friedegund Meier, Christian Busch, Thomas K. Eigentler, David Capper, Andreas Von Deimling, Michel Mittelbronn, Sven Perner, Kristian Ikenberg, Markus Hantschke, Petra Büttner, Claus Garbe, Benjamin Weide

Research output: Contribution to journalArticleResearchpeer-review

46 Citations (Scopus)

Abstract

The prognostic impact of BRAF-V600 tumor mutations in stage I/II melanoma patients has not yet been analyzed in detail. We investigated primary tumors of 437 patients diagnosed between 1989 and 2006 by Sanger sequencing. Mutations were detected in 38.7% of patients and were associated with age, histological subtype as well as mitotic rate. The mutational rate was 36.7% in patients with disease-free course and 51.7% in those with subsequent distant metastasis (p = 0.031). No difference in overall survival (p = 0.119) but a trend for worse distant-metastasis-free survival (p = 0.061) was observed in BRAF mutant compared to BRAF wild-type patients. Independent prognostic factors for overall survival were tumor thickness, mitotic rate and ulceration. An interesting significant prognostic impact was observed in patients with tumor thickness of 1 mm or less, with the mutation present in 6 of 7 patients dying from melanoma. In conclusion, no significant survival differences were found according to BRAF-V600 tumor mutations in patients with primary melanoma but an increasing impact of the mutational status was observed in the subgroup of patients with tumor thickness of 1 mm or less. A potential role of the mutational status as a prognostic factor especially in this subgroup needs to be investigated in larger studies.

Original languageEnglish
Article numbere86194
JournalPLoS ONE
Volume9
Issue number1
DOIs
Publication statusPublished - 24 Jan 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Survival according to BRAF-V600 tumor mutations - An analysis of 437 patients with primary melanoma'. Together they form a unique fingerprint.

Cite this